Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer (Q40807523)

23 September 2017

title

Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer (English)

1 reference

23 September 2017

main subject

metastatic breast cancer

1 reference

1 reference

1 reference

E H Moase

1 reference

23 September 2017

W Qi

1 reference

23 September 2017

T Ishida

1 reference

23 September 2017

Z Gabos

1 reference

23 September 2017

B M Longenecker

1 reference

23 September 2017

G L Zimmermann

1 reference

23 September 2017

L Ding

1 reference

23 September 2017

M Krantz

1 reference

23 September 2017

T M Allen

1 reference

23 September 2017

publication date

1 February 2001

1 reference

Biochimica et Biophysica Acta

23 September 2017

published in

1 reference

23 September 2017

volume

1510

1 reference

23 September 2017

issue

1-2

1 reference

23 September 2017

page(s)

43-55

1 reference

Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Anthracyclines in haematology: preclinical studies, toxicity and delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Immunoliposome-mediated targeting of anti-cancer drugs in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

High molecular weight epithelial mucins as markers in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Possible Utility of Serum Determinations of CA 125 and CA 27.29 in Breast Cancer Management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

A murine monoclonal antibody, MoAb HMSA-5, against a melanosomal component highly expressed in early stages, and common to normal and neoplastic melanocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Characterization of in vivo immunoliposome targeting to pulmonary endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Development of anti-p185HER2 immunoliposomes for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Demonstration of an extensive trans-tubular network continuous with the Golgi apparatus stack that may function in glycosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Anti-HER2 immunoliposomes for targeted therapy of human tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

Therapeutic agents for treatment of established metastases and inhibitors of metastatic spread: preclinical and clinical progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900334-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0005-2736(00)00334-5

1 reference

23 September 2017

1 reference